Idorsia Ltd
π¨πSwitzerland
A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ACT-1004-1239 (10 mg)
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05549531
- Locations
- π΅πΉ
BlueClinical Phase 1, Porto, Portugal
A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05480488
- Locations
- π©πͺ
Nuvisan GmbH, Neu-Ulm, Germany
A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05480475
- Locations
- π¨πΏ
CEPHA s.r.o., Pilsen, Czechia
A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep
Phase 1
Completed
- Conditions
- Obstructive Sleep Apnea of Adult
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05458193
- Locations
- π©πͺ
ASR Advanced Sleep Research GmbH, Berlin, Germany
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
Phase 2
Recruiting
- Conditions
- Insomnia
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05423717
- Locations
- π§π¬
MC Zdrave 1 Ltd., Kozloduy, Bulgaria
π§π¬University Hospital (UMHAT) Sveti Georgi, Plovdiv, Bulgaria
π§π¬MC ReSpiro Ltd., Razgrad, Bulgaria
A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05254548
- Locations
- π©πͺ
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Bioequivalence Study of Different Aprocitentan Tablet Formulations
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05196399
- Locations
- π¨πΏ
CEPHA s.r.o., Pilsen, Czechia
Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470
Phase 1
Completed
- Conditions
- Drug Drug InteractionHealthy
- Interventions
- Drug: Treatment period ADrug: Treatment period B
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05123820
- Locations
- π¨πΏ
CEPHA s.r.o., Pilsen, Czechia
The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05004311
- Locations
- π΅πΉ
BlueClinical Phase 1 Hospital de Prelado, Porto, Portugal
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Phase 3
- Conditions
- Acute Myocardial Infarction
- Interventions
- Combination Product: PlaceboCombination Product: Selatogrel
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14000
- Registration Number
- NCT04957719
- Locations
- π§πͺ
University Hospital Leuven (UZ Leuven), Leuven, Belgium
π§πͺAZ Delta Campus Rumbeke, Roeselare, Belgium
π¨π³Lianyungang First People's Hospital, Lianyungang, China
Β© Copyright 2025. All Rights Reserved by MedPath